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Abstract  
Poorly differentiated thyroid carcinoma (PDTC) is an independent thyroid cancer histotype. In spite of its scarcity, it represents the main cause of 
death from non-anaplastic follicular cell-derived thyroid cancer. However, given the newness of this entity, few data are available on its clinical 
behaviour and no explicit consensus sets its treatment. To report the experience of a tertiary medical centre in morocco with PDTC over a period of 
7 years. Retrospective study selecting all patients treated for thyroid carcinoma in Nuclear Medicine Department of a tertiary medical centre in 
Casablanca over seven years period. Patient's files were reviewed for background data, clinico-pathological characteristics, treatment and outcome. 
Seven patients were included in the study. Patient's average age was 60 years old (30-81) including six women and one man. All patients 
underwent a total thyroidectomy completed by cervical lymph node dissection in 57% of cases. Mean primary tumour size was 4cm (1-9cm). 
Patients were classified pT3 in 70% of cases, pT1 and pT2 in 15% each. Vascular invasion was found in 85% of cases. Pathological subtypes found 
were "insular carcinoma" in 85% of cases. Radioiodine therapy (RIT) was indicated in all cases. Follow-up period ranged between 10 months and 6 
years. It showed a complete remission in 57% of cases, persistent disease in 28% of cases and a progressive disease in 15% of cases with a local 
recurrence. To date, the survival rate is 85%. PDTC is an aggressive thyroid cancer histotype. Treatment remains surgical followed by RIT if the 
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Poorly differentiated thyroid carcinoma (PDTC) is a rare and 
independent thyroid cancer histotype. It was classified as a variant 
of well differentiated thyroid carcinoma (WDTC) until its recognition 
in 2004 by the World Health Organisation (WHO) as a distinct 
pathologic entity. It represents a heterogeneous group which clinical 
and histological features are not suitable to WDTC or Anaplastic 
carcinoma (AC). It's defined as "a follicular-cell neoplasm that shows 
limited evidence of structural follicular cell differentiation and occupy 
both morphologically and behaviourally an intermediate position 
between differentiated (follicular and papillary carcinomas) and 
undifferentiated (anaplastic) carcinoma" [1, 2]. In 2006, the 
international conference held in Turin - Italy - added more rigorous 
criteria known as "Turin criteria" to reach diagnosis standardization 
[2, 3]. PDTC definition includes both differentiation loss and high 
grade features. It is divided in three pathological subtypes: solid, 
insular, and trabecular [2- 4]. In spite of its scarcity, PDTC 
represents the main cause of death from "nonanaplastic follicular 
cell-derived thyroid cancer" [5]. However, given the newness of this 
entity, few data are available on its features and none of them 
involves patients in North Africa. To date, there is no explicit 
consensus to sets PDTC patients' management. This study intended 
to report the experience of a tertiary medical centre in Morocco by 
reporting patients' features, clinical stage at the time of diagnosis, 






The study involved all patients diagnosed histologically with PDTC 
among 3000 patients treated for thyroid carcinoma in Nuclear 
Medicine Department Ibn-Rochd University Hospital of Casablanca- 
Morocco- between January 2007 and December 2013. Histological 
diagnosis was based on "Turin criteria" [6]. The patients' medical 
data was analysed retrospectively. Files were reviewed for 
background data, clinico-pathological characteristics, treatment and 
outcome. Collected data: demographic data: gender, age; the 
revealing clinical sign; surgical treatment; histological features: 
histotype, tumour size, capsular invasion, vascular emboli, loco-
regional invasion and lymph node metastases; patients were staged 
according to the tumour node metastasis (TNM) classification-2010 
[7]; Iodine free diet and the thyroid hormone withdrawal were 
applied for at least four weeks prior to 131 iodine therapy and 
serum thyroglobulin (Tg) measurements. TSH level was kept above 
30µUI/ml; therapy dose was 3700 or 5550 MBq (100 or 150mCi) 
depending on the Tg levels and the presence of metastases, 131I 
whole body scan (WBS) was performed two days after radioiodine 
therapy to evaluate thyroid remnant and distant metastases. 
Additional imaging modalities were requested depending on WBS 
results. Follow-up by means of cervical examination, neck 
ultrasonography. Serum Tg checking and 131l WBS (with 111 MBq-
3mCi-of 131iodine) were done after thyroid hormone withdrawal 6 
to 9 months after RI. Interval between two therapies was higher 
than 6 months in repeated therapies. 
  
According to the results, patients were ranged in three groups: 
complete Remission: patients who completely responded to therapy 
with normal WBS and undetectable serum Tg (stimulated Tg levels 
below 1ng/ml); residual disease: positive or negative WBS results 
with positive Tg level reduced below the initial measurement; 
progressive disease: patients who are considered as non responders 
to therapy with positive or negative WBS results with unchanged or 





Among the 3000 thyroid carcinoma patients admitted in our 
department during the study period, seven patients were diagnosed 
with PDTC, 0.23% of our material. Patient's average age was 60 
years old (30- 81) including six women and one man. Four patients 
(57%) lived in non coastal areas. No radiation exposure history was 
reported. A cervical mass was noted in all cases at the admission 
without dysthyroidism signs. All patients were qualified for operative 
treatment. They underwent a total thyroidectomy, completed by 
cervical lymph node dissection in four cases (57%) showing regional 
lymph node involvement in all of them. The mean primary tumour 
size was 4 cm (1-9cm). According to AJCC staging, patients were 
classified pT3 in 70% of cases (capsular and peri-thyroidal fat 
invasion), and pT1 and pT2 in 15% each. Vascular invasion was 
found in 6 cases (85% of cases). Pathological subtypes found were 
"insular carcinoma" in 6 cases and "Trabecular carcinoma" in one 
case. The endogenous TSH stimulated Tg level prior RIT ranged 
between 3 and 65ng/ml in five cases (70%) and above 100ng/ml in 
three cases (30%) among them two had distant metastasis. Anti-
thyroglobulin antibodies were not dosed. WBS results after the first 
RIT showed a 131I neck uptake pointing the existence of thyroid 
remnants in all cases. It was associated with thoracic uptakes in one 
case, and both lung and bone (skull) uptakes in one another. 
Cumulative dose of radioiodine therapy was equal to 3700 MBq 
(100mCi) in four cases and 9250 MBq (250mCi) in three cases. The 
indication of successive doses of RIT resulted from the presence of 
radioavid metastasis. Follow-up period ranged between 10 months 
and 6 years. It showed: complete remission in four cases, half of 
them had a tumour staged T1-2 and all of them had a Tg level 
100ng/ml). In one case, the WBS and CT revealed local and cervical 
node recurrences. A third RIT is scheduled after the surgery. In the 
other, the WBS still show thoracic uptake after two RIT courses. CT 
scan showed bilateral pulmonary nodules. Scheduled for a third RIT; 
Progressive disease in one case with a local recurrence. This patient 
was a woman of 55 years old with a tumour staged initially: pT3 
N1b M+ (bone and lungs) with initial Tg measurement equal to 42 
ng/ml. She died one week after the second RIT. Last Tg level was 
4866ng/ml. The latest consultation showed a survival rate of 85%. 






This study group intended to report the experience of a tertiary 
Moroccan medical centre with PDTC, trying to add more information 
on its features. According to previous series, its incidence range 
between 4-7% among patients with thyroid carcinomas [5, 8]. The 
frequency of this tumour reaching 15% of thyroid carcinomas in 
some series in northern parts of Italy suggests the presence of 
genetic and /or environmental risk factors such as iodine deficiency 
in addition to radiation exposure [8]. In our study the incidence was 
0.23% and iodine deficiency may be considered as a risk factor, 
since more than half patients lived in non coastal regions, which are 
known for their iodine deficiency. PDTC should be considered a 
negative prognostic factor in patients with thyroid carcinoma.  
 
Histologically, its diagnosis is based on differentiation loss (non 
follicular - non papillary growth pattern), and high grade features 
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(invasive growth - high mitotic index and necrosis). PDTC displays 
predominant solid, insular, or trabecular growth patterns which can 
coexist with follicular, papillary or anaplastic carcinoma component 
[4, 9]. Indeed, according to the current models of tumour 
progression (WDTC evolving into PDTC then anaplastic carcinoma), 
the co-existence in the same tumour of WDTC with PDTC 
component may be seen. However, for PDTC diagnosis assessment, 
the majority of cell tumours must exhibit poorly differentiated 
features. Even though consensus conferences did not state a 
precise percentage yet, the quote adopted by authors is 75% [3, 
10]. It is however important to report the presence of PDTC 
component in an otherwise conventional WDTC since the high grade 
component may drive the prognosis [3]. In the current study, the 
mean age was 60 years with a high ratio of women (87%). These 
data support the fact that PDTC often occurs in the female gender 
in older age, most often in the sixth decade, consistently with the 
literature [5, 8, 11]. This study showed also the local and the 
distant aggressiveness of PDTC. When diagnosed, it was already at 
an advanced stage of disease, with extrathyroidal extension in 70% 
of cases, regional lymph nodes metastasis in more than half of 
cases and distant metastases in 43% of cases.  
 
According to previous studies and mainly the large series of 
Ibrahimpasic et al. [5], PDTC presents more frequently with invasive 
disease associated to lymph node metastasis. Distant spread is 
more commonly present in PDTC than WDTC with the same areas of 
predilection, namely bone and lungs. However, distant metastases 
may interest exceptionally unusual sites such as the skin, liver, 
ovaries, retro-peritoneum and intraocular [12, 13]. To date, there 
are no standard guidelines for PDTC management due to the 
previous lack of standard diagnostic criteria. Primary treatment 
commonly implemented remains the same than WDTC. It associates 
total thyroidectomy and lymph node dissection whenever feasible, 
since regional node metastasis are relatively frequent [14]. Adjuvant 
therapy such as RIT, External beam radiotherapy (EBRT) and 
chemotherapy remain poorly established. In the current study, all 
patients underwent total thyroidectomy and RIT. Neck dissection 
depended on preoperative and intra-operative determinations. RIT 
is a relatively harmless therapy which showed its effectiveness in 
WDTC. In PDTC, its indication is controversial. Even though poorly 
differentiated cells have the ability to trap radioiodine in more than 
80% of cases [9, 14], including distant metastasis at the time of 
diagnosis [5, 15], 15% of cases has a decreased iodine uptake, and 
consequently a limited RIT value. In our series, all cases showed 
radioavidity. Molecular pathways suggest that this iodine 
dysregulation of function may be due to BRAF mutation [16]. In 
addition, no statistical analysis did demonstrate RIT benefit on 
patient outcomes neither on their survival [5]. External beam 
radiotherapy (EBRT) utility in PDTC is still questionable. It is 
however indicated depending on locoregional recurrence risk, 
especially patients with positive margins, gross residual disease and 
regional lymph node metastasis with no distant metastasis [5]. It 
can be also used as a palliative treatment in bony metastases in 
whom RIT has failed [17]. Furthermore, Chemotherapy is reserved 
for inoperable cases. It contributes theoretically to loco regional 
control by improving respectability or by reducing disease 
progression [14] . In PDTC, patients' overall five years survival 
range between 50 - 89% [8, 15, 18, 19].  
 
In the study of Katsuhiro et al. which included 29 patients with 
PDTC, the specific 10 years survival was 89.9%. Volante et al. 
introduced a scoring system which ranks patients in three categories 
depending on three prognosis factors: patients age (> 45 years), 
mitotic index (>3/10HPF) and the presence of necrosis [18, 20] 
However, this scoring system is biased; it includes histological 
factors that are also considered as diagnostic marks. In the current 
study, unfavourable outcome seemed to be related to lymph node, 
distant metastases and to local recurrence. Univariate analysis in 
consecutive studies have included age, the high TNM stage, 
extrathyroidal extension, positive margins and distant metastasis as 





PDTC is an aggressive thyroid cancer histotype with high tendency 
to extrathyroidal extension, regional node and distant metastases. 
Treatment remains the same than WDTC with a neck dissection 
whenever feasible followed by RIT if the tumour is radioavid. A 
close monitoring is required to improve its outcome. Strengths 
and limitations of this study: to our knowledge, this is the first 
study treating the subject of Poorly Differentiated Thyroid 
Carcinoma in Morocco and in North Africa. This study is 
retrospective, monocentric based only on medical records. It is 
difficult to draw substantial conclusions from a small study group, 
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